Omega Therapeutics Leadership

Dr. Roger Sawhney joined Omega as Chief Financial Officer in August 2020. Prior to Omega, he served at KKR & Co. as Director of its healthcare investment platform in the Americas, where his work focused on investments across private and growth equity in the healthcare sector.

Earlier, he held the role of Senior Vice President and Head of Corporate Strategy for Novartis AG, as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health, a privately-funded leader in the digital health space. In these roles, Roger was progressively responsible for growth initiatives, M&A, business development and global strategic planning.

Dr. Sawhney has also served as Partner with both Bain and Company and the Boston Consulting Group, where he led and managed numerous investments across the life sciences, med-tech and digital health sectors, as well as transformation engagements for the world’s leading global biopharma companies. He has particular depth in M&A, BD&L, portfolio strategy and growth strategy.

He earned his M.D. degree from Harvard Medical School and also holds a BA in Economics from Stanford University.

Dr. Thomas McCauley joined Omega as chief scientific officer in August 2019. Prior to Omega, he served as CSO at Zikani Therapeutics (formerly Macrolide Pharmaceuticals) and before that at Translate Bio (formerly RaNA Therapeutics).

In these roles, Dr. McCauley was responsible for overall scientific vision, strategic direction and leadership of research and development. He provided scientific, technical and operational oversight for advancement of the company’s oligo, mRNA and novel macrocyclic technology platforms and management of portfolio therapeutic programs in pulmonary, metabolic, genetic and infectious disease.

Previously, Dr. McCauley served as vice president and head of Global Nonclinical Development at Shire Pharmaceuticals, where he made significant contributions to the development and global approvals of many of Shire's products, including Replagal® for Fabry disease, Vpriv® for Gaucher disease, Elaprase® for Hunter syndrome, Firazyr® for hereditary angioedema and Xiidra® for dry eye disease.

Dr. McCauley has more than 19 years of experience in the biotechnology and pharmaceutical industries and has authored more than 40 scientific publications, book chapters and patents. He holds undergraduate and graduate degrees from Cornell University and received his Ph.D. from the University of Alabama at Birmingham.

Kevin McManus joined Omega as Chief Human Resources Officer in March 2022. Prior to joining Omega, Kevin was most recently Senior Vice President and Chief Human Resources Officer at Acceleron Pharma, where he grew the organization to over 400 employees. Prior to this experience, he held various senior human resources roles of increasing responsibility at Bayer, most recently serving as Vice President and Human Resources Business Partner, Bayer Pharmaceuticals (Americas).

Previously, Kevin held senior human resources roles at Mylan Inc., The Ladders.com, ConvaTec, Inc., Bristol-Myers Squibb Company and GTE Corporation. In these roles, Kevin was responsible for leading internal human resources teams as well as expanding life science and biotechnology teams and attracting top talent by creating competitive programs and benefit policies.

Mr. McManus offers over 30 years of experience in many human resources roles supporting biotechnology, medical device and technology organizations, including over 15 years of experience leading global teams. His expertise lies in HR strategic planning, talent management, employee relations, M&A, and employee engagement retention. Kevin received his Bachelor of Science in Industrial and Labor Relations from Cornell University and certification as a Master Practitioner Organization Development from Ashridge University.

Dr. Yan Moore joined Omega as Chief Medical Officer in January 2022. Prior to Omega, he served as Senior Vice President, Head of Oncology Therapeutic Area at Ipsen Pharmaceuticals, and before that as Chief Medical Officer and Senior Vice President of Clinical Development and Research and Development at Anchiano Therapeutics (previously BioCanCell Therapeutics).

In these roles, Dr. Moore was responsible for identifying and executing research and development objectives in areas of oncology and immune-modulatory therapies, managing clinical and preclinical drug development (pre-IND to phase 1), scientific and development strategy, creation of internal drug development engines to support the overall portfolio strategies, and managing global medical affairs strategy.

Previously, Yan held several senior roles of increasing responsibility at Ariad Pharmaceuticals, Sanofi Oncology, GlaxoSmithKline, BMS amongst others. As a clinician, Dr. Moore spent time at Sapir Medical Center, Meir Hospital and Edith Wolfson Medical Center.

Dr. Moore has over 20 years of experience in the biotechnology and pharmaceutical industries. Dr. Moore received his medical degree and Bachelor of Medical Sciences from the Sackler School of Medicine at Tel Aviv University, Master of Business Administration from the LeBow College of Business at Drexel University and completed the Advanced Management Program at Harvard Business School.